EXHIBIT NO. 99
- --------------




CONTACT:

Trimeris Inc.                           Burns McClellan
Timothy J. Creech                       Jonathan M. Nugent (investors)
Director of Finance                     Justin Jackson (media)
(919) 419-6050                          (212) 213-0006


                      TRIMERIS ANNOUNCES MANAGEMENT CHANGES

DURHAM, NC, SEPTEMBER 7, 1999 - Trimeris, Inc. (NASDAQ:TRMS) announced today
that Matthew Megaro, President and Chief Financial Officer, has stepped down
from his positions at the Company to pursue other opportunities. Dani Bolognesi,
Trimeris' Chief Executive Officer, will assume the post of President and
continue as CEO of the Company. Robert Bonczek, a legal and business consultant
to Trimeris for the past two years, has been named Acting Chief Administrative
Officer and will also serve as Acting CFO. A search for an experienced CFO is
underway.

"We are grateful to Mr. Megaro for all his contributions towards the success of
Trimeris and his continuing support of the Company and wish him the very best in
his future endeavors," said Dani Bolognesi.

For the past two years, Mr. Bonczek has served as a legal and business
consultant to the Company. Prior to that, he spent 24 years at E. I. Dupont de
Nemours & Co. in various executive positions, including Chief Counsel and
Corporate Director of Safety, Health and Environmental Affairs.

"Mr. Bonczek has made a number of significant contributions to the Company over
the past two years in the areas of business development and strategic planning.
We are pleased that he has agreed to fill these roles within the Company,"
commented Dani Bolognesi.

Trimeris is a developmental stage, biopharmaceutical company engaged in the
discovery and development of novel therapeutic agents that block viral infection
by inhibiting viral fusion with host cells. The Company's lead product
candidate, T-20, which inhibits fusion of the human immunodeficiency virus (HIV)
with host cells, is currently in Phase II clinical trials and has received fast
track designation from the FDA. The Company's second product candidate, T-1249,
which also inhibits HIV fusion, has received fast track designation from the FDA
and is in a Phase I clinical trial.

Note: Except for any historical information presented herein, matters presented
in this release are forward-looking statements that involve risks and
uncertainties. The results of the Company's clinical trials are not necessarily
indicative of future clinical trials, and future results could differ materially
from the results presented herein. Factors that could cause or contribute to
such differences include, but are not limited to, those discussed in the "Risk
Factors" section included in the Company's Form 10-Q for the three months ended
March 31, 1999 filed with the Securities and Exchange Commission on May 17, 1999
and the Company's Registration Statement on Form S-3 as declared effective by
the Securities and Exchange Commission on May 26, 1999.